METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF PROSTATE CANCER

1 - 70 . (canceled)

71 . A method of detecting a prostate cancer-associated transcript in a cell from a patient, comprising:

providing a biological sample from the patient; and

contacting the biological sample with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Table 10.

72 . The method of claim 71 , wherein the polynucleotide selectively hybridizes to a sequence at least 95% identical to a sequence as shown in Table 10.

73 . The method of claim 71 , wherein the biological sample is a tissue sample.

74 . The method of claim 71 , wherein the biological sample comprises isolated nucleic acids, and the method further comprises amplifying the nucleic acids before the step of contacting the biological sample with the polynucleotide.

75 . The method of claim 71 , wherein the polynucleotide comprises a sequence as shown in Table 10.

76 . The method of claim 71 , wherein the polynucleotide is labeled.

77 . The method of claim 71 , wherein the polynucleotide is immobilized on a solid surface.

78 . The method of claim 71 , wherein the patient is undergoing a therapeutic regimen to treat prostate cancer and/or is suspected of having prostate cancer.

79 . A method of monitoring the efficacy of a therapeutic treatment of prostate cancer, comprising:

providing a biological sample from a patient undergoing the therapeutic treatment; and

determining the level of a prostate cancer-associated item in the biological sample by:

(a) contacting the biological sample with a contact polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Table 10, wherein the prostate cancer-associated item is a transcript, or

(b) contacting the biological sample with a contact polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Table 10, wherein the prostate cancer-associated item is an antibody and the contact polypeptide specifically binds to the antibody, or

(c) contacting the biological sample with a contact antibody, wherein the contact antibody specifically binds to a polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Table 10, wherein the prostate cancer-associated item is a polypeptide.

80 . The method of claim 79 , wherein the biological sample, is contacted with the contact polynucleotide, the method further comprising comparing the level of the prostate cancer-associated transcript to a level of the prostate cancer-associated transcript in a biological sample from the patient prior to, or earlier in, the therapeutic treatment.

81 . The method of claim 79 , wherein the biological sample is contacted with the contact polypeptide, the method further comprising comparing the level of the prostate cancer-associated antibody to a level of the prostate cancer-associated antibody in a biological sample from the patient prior to, or earlier in, the therapeutic treatment.

82 . The method of claim 79 , wherein the biological sample is contacted with the contact antibody, the method further comprising comparing the level of the prostate cancer-associated polypeptide to a level of the prostate cancer-associated polypeptide in a biological sample from the patient prior to, or earlier in, the therapeutic treatment.

83 . An isolated nucleic acid molecule consisting essentially of a polynucleotide sequence as shown in Table 10.

84 . An expression vector comprising a polynucleotide sequence as shown in Table 10.

85 . A host cell comprising an expression vector comprising a polynucleotide sequence as shown in Table 10.

86 . An isolated polypeptide which is encoded by a nucleic acid molecule having a polynucleotide sequence as shown in Table 10.

87 . An antibody that specifically binds a polypeptide which is encoded by a nucleic acid molecule having a polynucleotide sequence as shown in Table 10.

88 . The antibody of claim 87 or a fragment thereof, further conjugated to an effector component selected from the group consisting of a fluorescent label, a radioisotope, a cytotoxic chemical and combinations thereof.

89 . A method for identifying a compound that modulates a prostate cancer-associated polypeptide, comprising:

contacting the compound with a prostate cancer-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Table 10; and

determining the functional effect of the compound upon the polypeptide,

wherein the functional effect is a physical effect, a chemical effect or a combination thereof.

90 . A method of inhibiting proliferation of a prostate cancer-associated cell to treat prostate cancer in a patient, comprising:

providing a compound obtained from the method of claim 89 ; and

administering to the subject a therapeutically effective amount of the compound.

91 . A method for drug screening, comprising:

administering a test compound to a mammal having prostate cancer or a cell isolated therefrom; and

comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Table 10 in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell or mammal,

wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of prostate cancer.

92 . A method for treating a mammal having prostate cancer, comprising:

providing a compound identified by the method of claim 91 ; and

administering a therapeutically effective amount of the compound to the mammal.

93 . A pharmaceutical composition for treating a mammal having prostate cancer, comprising:

a compound identified by the method of claim 91 ; and

a physiologically acceptable excipient.

94 . A biochip comprising a plurality of polynucleotides that selectively hybridize to a sequence at least 80% identical to a sequence as shown in Table 10.